SRR12475154
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- P53_PATHWAY+0.280
- OXIDATIVE_PHOSPHORYLATION+0.210
- NOTCH_SIGNALING+0.180
- MYC_TARGETS_V2+0.170
- ADIPOGENESIS+0.140
- FATTY_ACID_METABOLISM+0.120
- MYC_TARGETS_V1+0.120
- MITOTIC_SPINDLE+0.110
- PEROXISOME+0.110
- DNA_REPAIR+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.360
- MTORC1_SIGNALING-0.340
- COMPLEMENT-0.300
- UV_RESPONSE_DN-0.290
- PROTEIN_SECRETION-0.270
- KRAS_SIGNALING_UP-0.250
- ALLOGRAFT_REJECTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168523 | — | — | 0.819 |
| 2 | TCGA-B6-A0X0-01A-21R-A115-07 | — | B | 0.804 |
| 3 | TCGA-60-2716-01A-01R-0851-07 | — | cohortSQ1 | 0.796 |
| 4 | R230 | — | — | 0.795 |
| 5 | SRR4296082 | — | cohortA1 | 0.795 |
| 6 | R32 | — | — | 0.786 |
| 7 | TCGA-34-2600-01A-01R-0851-07 | — | cohortSQ1 | 0.780 |
| 8 | 5cfccf66-7f7d-4385-96c8-8628a3cdbecb | — | — | 0.777 |
| 9 | cf2834ac-00ed-4372-be25-042f38241196 | — | — | 0.772 |
| 10 | R3 | — | — | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.210 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |